For the second quarter of 2026, analysts expect ATAI Life Sciences to report a consensus revenue of $0.11 million and an EPS of -$0.11, with the stock currently trading at $7.25 relative to an average price target of $10.90.
Investors are primarily focused on the pending $2.8 billion acquisition by Eli Lilly, which was announced in mid-July 2026. This buyout follows a period of clinical progress, including the initiation of the Phase 3 ReConnection program for BPL-003 targeting treatment-resistant depression.
The company maintains a robust cash position expected to fund operations into 2029, ensuring a significant runway for its remaining clinical pipeline throughout the acquisition process.